Research Analysts Set Expectations for CRVS FY2028 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities research analysts at HC Wainwright cut their FY2028 earnings per share estimates for Corvus Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst S. Lee now expects that the company will post earnings of $0.11 per share for the year, down from their prior forecast of $0.14. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ FY2029 earnings at $0.44 EPS.

Separately, Oppenheimer restated an “outperform” rating and set a $15.00 target price (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Corvus Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $12.63.

Corvus Pharmaceuticals Price Performance

CRVS stock opened at $3.35 on Thursday. The stock has a market capitalization of $215.26 million, a PE ratio of -3.60 and a beta of 0.91. The company has a 50 day moving average price of $4.67 and a 200 day moving average price of $6.08. Corvus Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06).

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of CRVS. Virtus ETF Advisers LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at $47,000. Nwam LLC bought a new stake in Corvus Pharmaceuticals in the third quarter valued at about $53,000. PKS Advisory Services LLC acquired a new position in Corvus Pharmaceuticals in the fourth quarter valued at about $56,000. Alpine Global Management LLC bought a new position in Corvus Pharmaceuticals during the fourth quarter worth about $62,000. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter worth about $72,000. 46.64% of the stock is owned by institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.